2024年肉瘤挑战会议(CCS):关于非循证管理方面的专家意见
2024年肉瘤挑战会议(CCS2024)采用德尔菲法在八个优先临床场景中识别出200个争议问题,64位专家在会议上讨论了141个争议,就24个关键诊疗问题达成强共识(>90%)、45个达成共识(>75%),未解决的争议强调需进一步研究。
要点
- 会议采用德尔菲法在八个优先临床场景中识别出200个争议问题。
- 64位专家讨论141个争议,24个问题达强共识(>90%),45个达共识(>75%)。
- 未解决的争议强调需要进一步研究。
核心结论
- CCS2024为临床决策提供了框架,并强调在罕见复杂恶性肿瘤治疗中共识驱动方法的重要性。
研究设计与样本
- 2024年肉瘤挑战会议(CCS2024)采用德尔菲法,在国际多学科肉瘤专家小组支持下,于八个优先临床场景中识别出200个争议问题,64位专家在会议上讨论了141个争议。
主要发现
- 专家就24个关键诊断和治疗问题达成强共识(>90%),就45个问题达成共识(>75%)。
- 未解决的争议强调需要进一步研究。
关键数值与推荐
- 强共识定义为>90%同意,共识定义为>75%同意。
- 八个优先临床场景包括腱鞘巨细胞瘤、四肢滑膜肉瘤、腹膜后肉瘤、血管肉瘤、叶状肿瘤、恶性外周神经鞘瘤、子宫平滑肌肉瘤和非典型脂肪瘤性肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未解决的争议强调需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical situations and scenarios without evidence remain controversial in daily practice. The 2024 Conference on Challenges in Sarcoma (CCS2024) aimed to narrow these gaps with the support of an international and multidisciplinary panel of sarcoma experts. METHODS: A Delphi process identified 200 controversial questions across eight prioritised clinical scenarios, including tenosynovial giant cell tumour, synovial sarcoma of the extremities, retroperitoneal sarcomas, angiosarcoma, phyllodes tumour, malignant peripheral nerve sheath tumour, uterine leiomyosarcoma, and atypical lipomatous tumour. RESULTS: Sixty-four experts discussed 141 controversies during the conference and reached strong consensus (> 90 %) on 24 and consensus (> 75 %) on 45 key diagnostic and therapeutic issues, while unresolved controversies emphasized the need for further research. CONCLUSIONS: CCS2024 provides a framework for clinical decision making and underscores the importance of consensus-driven approaches in the treatment of rare and complex malignancies.
引用
- Hofer S, Pauli C, Bode B, et al. Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects. Eur J Cancer. 2025. PMID: 40184845. doi:10.1016/j.ejca.2025.115368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。